Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease

Figure 4 Histological evaluation of hepatic tissue in different experimental groups and percentage description for the presence of microvesicular steatosis, macrovesicular steatosis, hypertrophy, inflammation, fibrosis and hepatocellular carcinoma. A and B: The images correspond to hematoxylin & eosin (H&E) and picrosirius red staining’s in the control group, showing a normal hepatic parenchyma with no significant changes; C and D: In the hepatocellular carcinoma (HCC)-group, animals exhibited macrovesicular steatosis and hypertrophy; E and F: Tumoral lesions with multiple fibrosis septa were observed in the HCC-group and rifaximin-group, as evidenced by H&E and picrosirius stained slides, respectively; G: Percentage description for the presence of microvesicular steatosis, macrovesicular steatosis, hypertrophy, inflammation, fibrosis, and HCC. Images A-D are magnified at 100 ×, and images E-F are magnified at 40 ×. HCC: Hepatocellular carcinoma; H&E: Hematoxylin & eosin; RIF: Rifaximin.